xvivo perfusion - XVIPF

XVIPF

Close Chg Chg %
33.45 -0.55 -1.64%

Closed Market

32.90

-0.55 (1.64%)

Volume: 100.00

Last Updated:

May 5, 2025, 11:36 AM EDT

Company Overview: xvivo perfusion - XVIPF

XVIPF Key Data

Open

$32.90

Day Range

32.90 - 32.90

52 Week Range

25.81 - 52.38

Market Cap

$987.51M

Shares Outstanding

31.50M

Public Float

24.49M

Beta

2.08

Rev. Per Employee

N/A

P/E Ratio

76.01

EPS

$0.41

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

349.50

 

XVIPF Performance

1 Week
 
-1.64%
 
1 Month
 
24.15%
 
3 Months
 
-15.64%
 
1 Year
 
3.65%
 
5 Years
 
N/A
 

XVIPF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About xvivo perfusion - XVIPF

Xvivo Perfusion AB is a medical technology company. It involves in developing and marketing solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation. Its products include XPS, XPS Disposable Kit, Steen Solution, Organ Chamber, Lung Cannula Set, Perfadex and Silicone Tubing Set. It operates through the Durable Goods and Non-Durable Goods segments. The Durable Goods segment includes sales and rental revenues from machines. The Non-Durable Goods segment covers sales of goods and services that are not durable goods. The company was founded by Magnus Nilsson on December 17, 1998 and is headquartered in Gothenburg, Sweden.

XVIPF At a Glance

Xvivo Perfusion AB
Mässans gata 10
Gothenburg, Vastra Gotaland 412 51
Phone 46-31-788-21-50 Revenue 77.79M
Industry Medical Specialties Net Income 16.29M
Sector Health Technology 2024 Sales Growth 38.196%
Fiscal Year-end 12 / 2025 Employees 180
View SEC Filings

XVIPF Valuation

P/E Current 76.006
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 85.602
Price to Sales Ratio 18.007
Price to Book Ratio 7.142
Price to Cash Flow Ratio 133.071
Enterprise Value to EBITDA 78.922
Enterprise Value to Sales 17.563
Total Debt to Enterprise Value 0.002

XVIPF Efficiency

Revenue/Employee 432,146.838
Income Per Employee 90,474.89
Receivables Turnover 6.094
Total Asset Turnover 0.357

XVIPF Liquidity

Current Ratio 4.58
Quick Ratio 3.299
Cash Ratio 2.341

XVIPF Profitability

Gross Margin 66.991
Operating Margin 14.056
Pretax Margin 24.312
Net Margin 20.936
Return on Assets 7.482
Return on Equity 8.39
Return on Total Capital 8.213
Return on Invested Capital 8.301

XVIPF Capital Structure

Total Debt to Total Equity 1.578
Total Debt to Total Capital 1.554
Total Debt to Total Assets 1.417
Long-Term Debt to Equity 1.072
Long-Term Debt to Total Capital 1.056
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Xvivo Perfusion - XVIPF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
30.10M 41.04M 56.29M 77.79M
Sales Growth
+54.04% +36.34% +37.16% +38.20%
Cost of Goods Sold (COGS) incl D&A
11.82M 13.05M 17.01M 25.68M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.76M 1.56M 2.91M 6.38M
Depreciation
1.29M 1.41M 2.19M 3.07M
Amortization of Intangibles
2.47M 148.91K 716.94K 3.31M
COGS Growth
+81.91% +10.40% +30.43% +50.91%
Gross Income
18.28M 27.99M 39.27M 52.11M
Gross Income Growth
+40.16% +53.11% +40.30% +32.69%
Gross Profit Margin
+60.74% +68.21% +69.77% +66.99%
2021 2022 2023 2024 5-year trend
SG&A Expense
18.79M 26.16M 35.65M 41.18M
Research & Development
3.61M 6.39M 12.18M 10.68M
Other SG&A
15.19M 19.77M 23.47M 30.50M
SGA Growth
+29.13% +39.24% +36.23% +15.52%
Other Operating Expense
- - - -
-
Unusual Expense
2.29M 1.41M 3.63M 2.58M
EBIT after Unusual Expense
(2.80M) 418.58K (3.39K) 8.35M
Non Operating Income/Expense
3.61M 1.89M 9.02M 11.09M
Non-Operating Interest Income
- 209.78K 833.65K 1.62M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
32.15K 108.10K 112.10K 529.76K
Interest Expense Growth
-47.34% +236.25% +3.69% +372.60%
Gross Interest Expense
32.15K 108.10K 112.10K 529.76K
Interest Capitalized
- - - -
-
Pretax Income
776.38K 2.20M 8.90M 18.91M
Pretax Income Growth
+112.48% +184.00% +303.80% +112.40%
Pretax Margin
+2.58% +5.37% +15.82% +24.31%
Income Tax
(173.22K) 384.09K 254.43K 2.63M
Income Tax - Current - Domestic
(119.05K) 90.42K 1.36M 778.32K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(54.17K) 293.68K (1.10M) 1.85M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
949.60K 1.82M 8.65M 16.29M
Minority Interest Expense
- - - -
-
Net Income
949.60K 1.82M 8.65M 16.29M
Net Income Growth
+119.99% +91.75% +375.01% +88.29%
Net Margin Growth
+3.15% +4.44% +15.37% +20.94%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
949.60K 1.82M 8.65M 16.29M
Preferred Dividends
- - - -
-
Net Income Available to Common
949.60K 1.82M 8.65M 16.29M
EPS (Basic)
0.0329 0.0617 0.2889 0.517
EPS (Basic) Growth
+118.81% +87.54% +368.23% +78.95%
Basic Shares Outstanding
28.85M 29.53M 29.94M 31.50M
EPS (Diluted)
0.0328 0.0617 0.2889 0.5145
EPS (Diluted) Growth
+118.75% +88.11% +368.23% +78.09%
Diluted Shares Outstanding
28.94M 29.53M 29.94M 31.65M
EBITDA
3.25M 3.39M 6.53M 17.31M
EBITDA Growth
+5,905.38% +4.31% +92.86% +164.92%
EBITDA Margin
+10.79% +8.26% +11.61% +22.25%

Xvivo Perfusion in the News